You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,962,860


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,962,860
Title:Inhibitors of glutaminyl cyclase
Abstract: Compounds of general formula (I): ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X and Y are as defined herein are inhibitors of glutaminyl cyclase and are therefore useful in treating conditions that can be treated by modulation of glutaminyl cyclase activity.
Inventor(s): Heiser; Ulrich (Halle/Saale, DE), Sommer; Robert (Halle/Saale, DE), Gaertner; Ulf-Torsten (Halle/Saale, DE), Hamann; Antje (Dieskau, DE), Almstetter; Michael (Martinsried, DE), Thormann; Michael (Martinsried, DE), Treml; Andreas (Martinsried, DE), Demuth; Hans-Ulrich (Halle/Saale, DE), Hoffman; Torsten (Halle/Saale, DE)
Assignee: Probiodrug AG (Halle-Saale, DE)
Application Number:12/554,611
Patent Claims:1. A compound of formula (I): ##STR00097## or a pharmaceutically acceptable salt thereof, including all tautomers and stereoisomers thereof wherein: R.sup.1 represents ##STR00098## or imidazolyl-C.sub.1-4alkyl wherein the imidazole ring is optionally substituted by methyl; R.sup.2 represents (i) phenyl which is optionally substituted by one or more groups selected from C.sub.1-6alkyl, C.sub.1-6haloalkyl, C.sub.1-6alkoxy, C.sub.1-6alkoxy-C.sub.1-6alkyl-, halogen, and hydroxyl; or (ii) phenyl substituted by phenyl; R.sup.3 represents H; R.sup.4 represents H or --C.sub.1-4alkyl; X represents O or S; and Y represents O or S.

2. A compound according to claim 1, wherein R.sup.1 represents: ##STR00099##

3. A compound according to claim 1, wherein R.sup.1 represents: ##STR00100## wherein A represents an unbranched or branched C.sub.1-4alkylene chain or a branched C.sub.1-4alkylene chain; and R.sup.11, R.sup.12 and R.sup.13 independently represent H or methyl.

4. A compound according to claim 1 represented by the formula: ##STR00101## wherein R.sup.2, R.sup.3, R.sup.4, X and Y are as defined in claim 1.

5. A compound according to claim 1, wherein R.sup.2 is -biphenyl-4-yl.

6. A compound according to claim 1, wherein R.sup.2 represents phenyl optionally substituted by one, two, or three substituents, which may be the same or different and are chosen from halogen, OH, C.sub.1-3alkyl, C.sub.1-3haloalkyl, and C.sub.1-3alkoxy.

7. A compound according to claim 6, wherein R.sup.2 is phenyl substituted by n-propyloxy.

8. A compound according to claim 1, wherein R.sup.4 represents H.

9. A compound according to claim 1, wherein X represents O.

10. A compound according to claim 1, wherein Y represents O.

11. A compound according claim to 1, wherein the compound of formula (I) is represented by ##STR00102## wherein R.sup.2 and R.sup.3 are as defined in claim 1.

12. A compound according to claim 1 selected from the group consisting of: 1-(1H-benzo[d]imidazol-5-yl)-5-phenylimidazolidine-2,4-dione; 1-(1H-benzo[d]imidazol-5-yl)-5-(2-hydroxy-5-methylphenyl)imidazolidine-2,- 4-dione; 1-(1H-benzo[d]imidazol-5-yl)-5-(2-fluoro-5-trifluoromethylphenyl)- imidazolidine-2,4-dione; 1-(1H-benzo[d]imidazol-5-yl)-5-(2-bromo-5-fluorophenyl)imidazolidine-2,4-- dione; 1-(1H-benzo[d]imidazol-5-yl)-5-(4-propoxyphenyl)imidazolidine-2,4-d- ione; 1-(1H-benzo[d]imidazol-5-yl)-5-(4-chloro-3-trifluoromethylphenyl)imi- dazolidine-2,4-dione; 1-(1H-benzo[d]imidazol-5-yl)-5-(3-fluoro-4(trifluoromethyl)phenyl)imidazo- lidine-2,4-dione; 1-(1H-benzo[d]imidazol-5-yl)-5-(3-hydroxy-4-methoxyphenyl)imidazolidine-2- ,4-dione; 1-(1H-benzo[d]imidazol-5-yl)-5-(2-hydroxy-3-methoxyphenyl)imidaz- olidine-2,4-dione; 1-(1H-benzimidazol-5-yl)-5-(1,1'-biphenyl-4-yl)imidazolidine-2,4-dione; 1-(1H-benzo[d]imidazol-5-yl)-5-(3-chlorophenyl)imidazolidine-2,4-dione; 1-(1H-benzo[d]imidazol-5-yl)-5-(4-chlorophenyl)imidazolidine-2,4-dione; 1-(1H-benzo[d]imidazol-5-yl)-5-(2-chlorophenyl)imidazolidine-2,4-dione; 1-(1H-benzo[d]imidazol-5-yl)-5-(4-fluorophenyl)imidazolidine-2,4-dione; 1-(3-(1H-imidazol-1-yl)propyl)-5-phenylimidazolidine-2,4-dione; 1-(3-(1H-imidazol-1-yl)propyl)-5-(2-bromo-4-fluorophenyl)imidazolidine-2,- 4-dione; 1-(3-(1H-imidazol-1-yl)propyl)-5-(4-propoxyphenyl)imidazolidine-2- ,4-dione; 1-(3-(1H-imidazol-1-yl)propyl)-5-(3-fluoro-4-(trifluoromethyl)ph- enyl) imidazolidine-2,4-dione; 1-[3-(1H-imidazol-1-yl)propyl]-5(4-biphenyl)imidazolidine-2,4-dione; 1-(3-(1H-imidazol-1-yl)propyl)-5-(3-chlorophenyl)imidazolidine-2,4-dione; 1-(3-(1H-imidazol-1-yl)propyl)-5-(2-chlorophenyl)imidazolidine-2,4-dione; 1-(3-(5-methyl-1H-imidazol-1-yl)propyl)-5-phenylimidazolidine-2,4-dione; 5(2-bromo-5-fluorophenyl)-143(5-methyl-1H-imidazol-1-yl)propyl)imidazolid- ine-2,4-dione; 1-(3-(5-methyl-1H-imidazol-1-yl)propyl)-5-(4-propoxyphenyl)imidazolidine-- 2,4-dione; 1-[3-(5-methyl-1H-imidazol-1-yl)propyl]-5-(4-phenylphenyl)imida- zolidine-2,4-dione; 5(3-chlorophenyl)-1-(3-(5-methyl-1H-imidazol-1-yl)propyl)imidazolidine-2,- 4-dione; 1-(3-(4-methyl-1H-imidazol-1-yl)propyl)-5-phenylimidazolidine-2,4- -dione; 1-[3-(4-methyl-1H-imidazol-1-yl)propyl]-5(4-biphenyl)imidazolidine- -2,4-dione; 5(3-chlorophenyl)-1-(3-(4-methyl-1H-imidazol-1-yl)propyl)imidazolidine-2,- 4-dione; 1-(1H-benzo[d]imidazol-5-yl)-5-phenyl-2-thioxoimidazolidin-4-one; 1-(1H-benzimidazol-5-yl)-5-(1,1'-biphenyl-4-yl)-2-thioxoimidazolidin-4-on- e; 1-(1H-benzo[d]imidazol-5-yl)-5-(3-hydroxy-4-methoxyphenyl)-2-thioxoimid- azolidin-4-one; 1-(1H-benzo[d]imidazol-5-yl)-5-phenyl-4-thioxoimidazolidin-2-one; 1-(1H-benzimidazol-5-yl)-5-(1,1'-biphenyl-4-yl)-4-thioxoimidazolidin-2-on- e; 1-(1H-benzo[d]imidazol-5-yl)-5-(2,3,4-trifluorophenyl)-4-thioxoimidazol- idin-2-one; 1-(1H-benzo[d]imidazol-6-yl)-5-(4-bromo-2-fluorophenyl)-4-thioxoimidazoli- din-2-one; 1-(1H-benzo[d]imidazol-5-yl)-5-(2,3-difluoro-4-methylphenyl)-4-- thioxoimidazolidin-2-one; 1-(1H-benzo[d]imidazol-5-yl)-5-(4-chloro-3-methylphenyl)-4-thioxoimidazol- idin-2-one; and 1-(H-imidazo[1,2-a]pyridin-7-yl)-5-phenylimidazolidine-2,4-dione; or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.

13. A compound according to claim 1 which is 1-(1H-benzo[d]imidazol-5-yl)-5-(4-propoxyphenyl)imidazolidine-2,4-dione, having a structure of: ##STR00103##

14. A process for the preparation of a compound of claim 1 comprising one of: a) reacting a compound of formula (II) by converting an imine to a carbonyl under aqueous conditions to give a compound of formula (I) wherein X is O and R.sup.4 is H; R.sup.1, R.sup.2, R.sup.3 and Y are as defined in claim 1; and R represents alkyl ##STR00104## b) reacting a compound of formula (II) with a source of sulfide ions to give a compound of formula (I) wherein X is S and R.sup.4 is H; or c) reacting a compound of formula (VIII), wherein R.sup.1 and R.sup.4 are as defined in claim 1; ##STR00105## with a compound of formula (IX), wherein R.sup.2 is as defined in claim 1; ##STR00106## to give a compound of formula (I), wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and Y are as defined in claim 1; and X represents O; or d) reacting a compound of formula (XIII), wherein R.sup.1, R.sup.2 and R.sup.3 are as defined in claim 1; ##STR00107## with a compound of formula (XIV), wherein (i) J and K both represent H; (ii) J and K both represent a leaving group; or (iii) J represents alkoxy and K represents a halogen; ##STR00108## to give a compound of formula (I) wherein R.sup.1, R.sup.2R.sup.3, R.sup.4 and Y are as defined above and X represents O.

15. A pharmaceutical composition comprising: a compound according to claim 1; and one or more pharmaceutically acceptable diluents or carriers.

16. A pharmaceutical composition according to claim 15 further comprising at least one compound selected from the group consisting of neuroprotectants, antiparkinsonian drugs, amyloid protein deposition inhibitors, beta amyloid synthesis inhibitors, antidepressants, anxiolytic drugs, antipsychotic drugs and anti-multiple sclerosis drugs.

17. A pharmaceutical composition according to claim 15 further comprising at least one compound selected from the group consisting of PEP-inhibitors, LiCl, inhibitors of inhibitors of DP IV or DP IV-like enzymes, acetylcholinesterase (ACE) inhibitors, PIMT enhancers, inhibitors of beta secretases, inhibitors of gamma secretases, inhibitors of neutral endopeptidase, inhibitors of Phosphodiesterase-4 (PDE-4), TNFalpha inhibitors, muscarinic M1 receptor antagonists, NMDA receptor antagonists, sigma-1 receptor inhibitors, histamine H3 antagonists, immunomodulatory agents, immunosuppressive agents or an agent selected from the group consisting of antegren (natalizumab), Neurelan (fampridine-SR), campath (alemtuzumab), NBI 5788/MSP 771 (tiplimotide), paclitaxel, Anergix.MS (AG 284), SH636 (mesopram), Differin (CD 271, adapalene), BAY 361677 (interleukin-4), matrix-metalloproteinase-inhibitors, interferon-tau (trophoblastin) and SAIK-MS.

Details for Patent 8,962,860

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Jubilant Hollisterstier Llc N/A positive skin test control-histamine Injection 103891 03/13/1924 ⤷  Try a Trial 2028-09-04
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 05/07/2001 ⤷  Try a Trial 2028-09-04
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 11/14/2014 ⤷  Try a Trial 2028-09-04
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 10/12/2004 ⤷  Try a Trial 2028-09-04
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.